A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine as Adjuvant to Opioids in Terminally Ill Cancer Patients With Refractory Cancer Pain (CIVIK Trial).

Kownoh ParkJae-Joon KimSang-Bo OhSo Yeon OhYun Jeong HongSeo-Jun KimEun-Ju ParkNayeon ChoiSeon-Hi ShinSungeun KimHeejung Ko

Published in: The American journal of hospice & palliative care (2024)

This study showed efficacy of gradually increasing CIVI of ketamine for terminally ill cancer patients with refractory cancer pain. CIVI of ketamine could be a useful tool in these patients considering the limited treatment options. (NCT03362073, Initial Release: November 15, 2017).

Keyphrases

papillary thyroid
pain management
chronic pain
squamous cell
phase ii study
end stage renal disease
chronic kidney disease
early stage
ejection fraction
newly diagnosed
clinical trial
low dose
high dose
squamous cell carcinoma
spinal cord injury
peritoneal dialysis
prognostic factors
rectal cancer